New bioavailability study underlines OmeGo®’s ability to unlock the full potential of fresh, whole fish compared to processed 18/12 omega-3 oils

New research has cemented the reputation of Hofseth BioCare’s OmeGo^® ingredient as being a complete, uncompromising nutritional solution that can unlock the full health benefits of eating whole fish.

The new study, published in Biomedical, found that two natural marine oils - OmeGo^® (a full spectrum salmon oil with all 21 fatty acids and omegas) and krill oil – demonstrated greater absorbability of fatty acids EPA and DHA compared to processed 18/12 omega-3 oil.

The findings revealed that the marine oils significantly increased serum DHA and EPA levels in an animal model over a seven-day trial period – with absorbability two to four times greater than with traditional 18/12 omega-3 oil. For supplement formulators and manufacturers, this is important as it suggests that optimal DHA and EPA levels in the blood can be achieved with a much smaller dose of OmeGo^® versus processed oils.

Natural triglyceride (TG) forms of the fatty acids present in both marine oils were therefore easier for the gastrointestinal tract to digest and absorb than the reconstituted ethyl ester form (EE) found in processed oils. Ethyl esters require further digestion in the gut compared to natural TGs, which can significantly impact their bioavailability and overall health benefits.

This suggests that natural marine oils are significantly more bioavailable than processed oils and therefore more likely to deliver all the health benefits associated with eating fresh, whole fish.

Minimally processed with low levels of oxidation, OmeGo® contains the full spectrum of 21-omegas and polyunsaturated fatty acids found in fish - not just omega-3.

Dr Crawford Currie, Head of Medical R&D at Hofseth BioCare, said: “Ultimately, these findings confirm that processing damages the quality and integrity of the oil, and therefore its nutritional profile. As well as being heavily processed, most fish oil concentrates on just one or two elements of whole fish, which limits the overall health benefits.”

“These findings strengthen the growing bank of evidence that OmeGo® is the closest consumers can get to consuming fresh, whole fish, offering a more extensive, varied and readily available health benefit profile than traditional supplementation widely available on the market today. OmeGo® therefore represents a more promising route to bridging the omega-3 gap prevalent in typical western diets today.

However, the benefits of OmeGo® go beyond omega-3 and it is unmatched in terms of meeting consumer demand for optimal nutritional performance, minimal ecological impact and better affordability.”

Unlike other fish oils, OmeGo® contains all essential omega fatty acids and a unique lipopeptide, which together have been shown ​to enhance cardiovascular health, restore respiratory health, support joint health and improve immune health.

Hofseth Biocare’s end-to-end traceability system offers full visibility over the sustainable production process, providing peace of mind to conscious consumers. Furthermore, switching to OmeGo® could help improve accessibility for consumers, with cost of use also more competitive than the average krill oil on the market.

This new study builds on other promising results demonstrating that OmeGo® has been shown to improve bioavailability of vitamin A and E, as well as lutein and zeaxanthin. A larger-scale study is now in the pipeline to further assess the bioavailability, inflammation-resolution and microbiome effects of OmeGo® and processed omega-3 oil.

For more information, contact the Hofseth BioCare team here: Hofseth BioCare | Research and development